Recommendation ID
IPG459/1
Question
NICE encourages research to guide future use of selective internal radiation therapy (SIRT) for primary intrahepatic cholangiocarcinoma. This should document patient characteristics, tumour response, survival and quality of life measures, and details of other treatments used adjunctively or sequentially. NICE may review the procedure on publication of further evidence.
Any explanatory notes
(if applicable)
Current evidence on the safety and efficacy of selective internal radiation therapy (SIRT) for primary intrahepatic cholangiocarcinoma is limited in both quantity and quality. Therefore this procedure should only be used with special arrangements for clinical governance, consent and audit or research. Patients with primary intrahepatic cholangiocarcinoma should be selected for treatment by SIRT or for entry into trials by a multidisciplinary hepatobiliary cancer team.

Source guidance details

Comes from guidance
Selective internal radiation therapy for primary intrahepatic cholangiocarcinoma
Number
IPG459
Date issued
July 2013

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 31/07/2013